Kailera Therapeutics posted its second-quarter update on August 12, 2026, and buried in the business section is the clearest picture yet of the obesity drug most US readers have never heard of: ribupatide (KAI-9531), a GLP-1/GIP dual agonist that has already cleared a 567-person Phase 3 trial in China and is now enrolling more than 4,700 people across three global Phase 3 studies.
It is the same receptor pairing as tirzepatide, it comes in both an injectable and an oral form, and it is being run by a company with $1.17 billion in the bank. It is also, for anyone reading this in the US, completely unobtainable — and the gap between those two facts is the whole story.
Research-context information only. This article reports published trial data, company disclosures and regulatory filings as they stand. Ribupatide is an investigational molecule that is not approved by the FDA or any other regulator, and it has not been evaluated for safety, purity or potency for human use. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Nothing here is medical advice or a recommendation to use any compound. Consult a licensed physician before making any decision about a GLP-1 protocol.
What Kailera disclosed on August 12
Ribupatide was discovered by Jiangsu Hengrui Pharmaceuticals in China as HRS9531 and licensed to Kailera Therapeutics for development everywhere outside Greater China, where it carries the designation KAI-9531. Hengrui runs the China program; Kailera runs the global one. That split is why the trial record reads strangely — the large efficacy data comes from China, while the US program is still early.
The Q2 release confirmed four things:
- The global Phase 3 injection program is enrolling. KaiNETIC-1, KaiNETIC-2 and KaiNETIC-3 together target more than 4,700 participants, testing once-weekly subcutaneous ribupatide at doses up to 10 mg over 76 weeks — up to 24 weeks of titration followed by at least 52 weeks of maintenance. KaiNETIC-3 includes an open-label semaglutide 2.4 mg comparison arm. Data is expected in 2028.
- The oral version has an active US IND. Kailera reported the Investigational New Drug application for oral ribupatide is active with the FDA, with Phase 3 initiation planned for the first half of 2027.
- A higher-dose injection readout lands sooner. Phase 2b high-dose injection data is guided for mid-2027.
- Cash runs to mid-2028. Kailera reported $1,171.8 million in cash, cash equivalents and marketable securities, funding operations into mid-2028 — enough to reach the Phase 3 readout without raising again.
None of that is a surprise on its own. What makes it worth writing up is that it locks in the timeline: there is no path by which ribupatide becomes a purchasable product in the US this decade's first half.
The number that actually matters
Search results for ribupatide are dominated by a single figure — 23.6% weight loss — and it is worth understanding where that number came from, because the larger trial produced a smaller one.
| Trial | n | Dose | Duration | Weight loss |
|---|---|---|---|---|
| Phase 2, China (injection) | 61 | titrated to 8 mg | 36 weeks | 22.8% from baseline (21.1% placebo-adjusted) |
| Phase 3 HRS9531-301, China (injection) | 567 | 2 / 4 / 6 mg | 48 weeks | 17.7% from baseline (16.3% placebo-adjusted); 19.2% at 6 mg in a prespecified supplementary analysis |
| Phase 2, China (oral tablet) | — | 10 / 25 / 50 mg | 26 weeks | 6.9% / 12.1% / 12.1% vs 2.3% placebo |
| Phase 1, global (injection) | 49 | single 1-3 mg dose | 29 days | 1.4-5.5% vs 0.4% placebo |
The Phase 2 injection trial randomised 61 people 4:1, meaning 49 actually received the drug. It titrated to 8 mg over 24 weeks and held that dose for only 12 weeks, and reported 22.8% mean reduction from baseline at week 36 with no plateau — 59% of participants lost at least 20% of body weight. Kailera's own later materials describe the same trial as a 23.6% reduction from baseline against 1.8% on placebo. Both figures come from a study of 49 treated people.
The Phase 3 was ten times larger, ran 12 weeks longer, and topped out at a lower 6 mg dose. It reported a mean 17.7% reduction across doses at 48 weeks, 16.3% placebo-adjusted, with the 6 mg arm reaching 19.2% in a prespecified supplementary analysis. About 88% of treated participants lost at least 5% of body weight and 44.4% lost at least 20%. It met both primary endpoints.
So the honest read is that ribupatide's confirmed, adequately-powered result is roughly 17-19% over 48 weeks, and the eye-catching 22.8-23.6% is a small early-phase result at a dose the Phase 3 never tested. That is not a knock on the molecule — it is why KaiNETIC pushes to 10 mg over 76 weeks. It is simply the difference between a signal and a confirmed effect.
Where it sits against what already exists
Placed against the compounds people actually have access to, ribupatide's confirmed data lands in the middle of the field rather than at the top of it:
| Compound | Class | Reported weight loss | Status |
|---|---|---|---|
| Retatrutide | GLP-1/GIP/glucagon triple | ~28.7% at 68 weeks (12 mg, TRIUMPH-4) | Phase 3, unapproved |
| Tirzepatide | GLP-1/GIP dual | ~22.5% at 72 weeks | Approved |
| Ribupatide | GLP-1/GIP dual | 17.7-19.2% at 48 weeks (6 mg) | Phase 3, unapproved |
| Semaglutide | GLP-1 | ~15% at 68 weeks | Approved |
Cross-trial comparisons are imprecise — different populations, different baselines, different durations — so treat this as orientation, not a ranking. The structural point holds regardless: ribupatide is a second entrant in the class tirzepatide already defined, and its case rests on whether the higher 8-10 mg doses hold up in a large population. That answer arrives in 2028.
For a fuller breakdown of the triple agonist at the top of that table, see our retatrutide Phase 3 results coverage.
What this means for readers looking to buy
The practical answer is short: ribupatide is not for sale, anywhere, in any form. It is not approved in a single country, there is no compounding pathway for an investigational molecule with no approved reference product, and it does not appear in our vendor offer database. We have not seen a COA-backed ribupatide listing on any vendor we track.
One distinction matters here, though. Ribupatide is a peptide, not a small-molecule pill — which means it is synthesizable in a way that, say, an oral small molecule is not. Listings under "HRS9531," "HRS-9531" or "KAI-9531" could plausibly surface at some point the way retatrutide listings did. If and when they do, the things worth checking are the same as for any early compound: a batch-specific third-party COA with HPLC purity and mass-spec identity, a stated mass that matches the vial, and a vendor with a track record on compounds that can already be verified. Until that documentation exists, there is nothing to evaluate.
For readers drawn here by the weight-loss number rather than the molecule specifically, the class it belongs to is well covered by compounds that ship today:
- Best Tirzepatide Vendors — the same GLP-1/GIP dual-agonist mechanism ribupatide uses, with current pricing on 10mg, 30mg and 60mg vials
- Best Retatrutide Vendors — the triple agonist with the highest reported trial numbers to date
- Best Semaglutide Vendors — pricing on 5mg and 10mg vials
- All Active Vendor Coupons — current discount codes across recommended vendors
